Outcomes
The 5-year PFS was 70.99% (95% CI, 58.22%-90.42%) and the 5-year OS
was 72.99% (95% CI, 60.41%-93.06%) for MTX group, while those for
control group were 41.67% (95% CI, 17.93%-66.92%) and 50% (95% CI,
27.88%-77.14%), respectively. Upon Chi-square test, there was a
significant difference in the excellent response rate between the two
groups when comparing PFS and OS (p < 0.05).
OS was noted in children with R0 resection (HR: 0.48, 95% CI:
0.0053-33.29), M0 status (HR: 0.59, 95% CI: 0.00092-28.87), no diffuse
anaplasia histology (HR: 0.14, 95% CI: 0.0058-1.53) and MTX intrathecal
injection (HR: 0.49, 95% CI: 0.099-2.49).
In the meantime, PFS was noted among children with R0 resection (HR:
0.46, 95% CI: 0.0052-31.26), M0 status (HR: 0.44, 95% CI:
0.0069-21.49), no diffuse anaplasia histology (HR: 0.14, 95% CI:
0.0060-1.52) and MTX intrathecal injection (HR: 0.67, 95% CI:
0.141-3.39).
However, none of the above four factors was identified as the
significant risk factors for OS or PFS ( p > 0.05).